Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Astellas Pharma Europe B.V
Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
Enzalutamide Treatment of Metastatic Castration-Resistant Prostate Cancer Patients after Abiraterone Acetate Tratamiento con enzalutamida del cáncer de próstata progresivo y metastásico resistente a la castración tras acetato de abiraterona
Evaluation of radiographic progression-free survival (rPFS) Evaluar la supervivencia sin progresión radiográfica (SSPr)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability with Warfarin
The primary objective is to investigate the optimal daily dose and dose regimen of YM150 in subjects with NVAF, primarily based on safety and tolerability data.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
This is a short study, performed in different countries, to investigate how well one dose of mirabegron in tablet form is taken up, how long it stays in the body and how well it will be tolerated in children/adolescents aged 5 to less than 18 years with symptoms of neurogenic detrusor overactivity or overactive bladder
To evaluate the pharmacokinetics of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V. (APEB)
MAJ Il y a 4 ans
A study to evaluate the effect on pain relief and safety of a new treatment (ASP8477) with a mock treatment (placebo) in subjects with Peripheral Neuropathic Pain
To assess analgesic efficacy of ASP8477 relative to placebo in subjects with peripheral neuropathic pain as determined by the change in the average daily pain intensity in responders.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)
MAJ Il y a 4 ans
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia
To assess the effect of Tamsulosin OCAS 0.4 mg o.d. compared to placebo on improvement of nocturnal voiding frequency, in subjects with LUTS associated with BPH over 12 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
Roxadustat in the treatment of anemia in end stage renal disease patients on stable dialysis
Evaluate the efficacy of roxadustat compared to epoetin alfa and darbepoetin alfa in the maintenance treatment of anemia in End Stage Renal Disease (ESRD) subjects on stable dialysis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis
To evaluate the efficacy and safety of YM672 administered orally in the treatment of painful bladder syndrome (PBS)/interstitial cystitis (IC). The primary efficacy endpoint is success, defined as ‘Mo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
A study to investigate how effective and safe the study medication ‘mirabegron’ is and how long it stays in the body in children and adolescents aged 3 to less than 18 years with symptoms of an overactive bladder with a neurologic cause
To evaluate the efficacy of mirabegron after multiple-dose administration in the pediatric population.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes
• To evaluate the safety and tolerability of different doses and dose regimens of YM150 on top of standard treatment with Acetyl Salicylic Acid (ASA) with or without clopidogrel in the secondary preve...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open label enoxaparin (Study no. 150-CL-008) Protocol for Phase 2B Study of YM150
To investigate the optimal therapeutic dose by evaluation of the efficacy of YM150 in subjects undergoing elective primary hip replacement (HR) surgery. Evaluation of the safety of YM150 in the targ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
Suivant